ClinicalTrialsFinder

High Risk of Recurrence Clinical Trials in Nanjing, Jiangsu

1 recruitingNanjing, Jiangsu, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma (HCC)Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation
The First Affiliated Hospital with Nanjing Medical University276 enrolled1 locationNCT06762782